TY - JOUR
AU - Uesaka, Katsuhiko
AB - INTRODUCTIONPancreatic cancer (PC) is associated with a poor prognosis and an overall 5‐year survival rate of <10%.1 It is the third‐leading cause of cancer mortality in Japan.1 Surgery is the most effective treatment and offers the only chance for a cure of nonmetastatic PC; however, recurrence rates are high, even after curative resection. The CONKO‐0012 and JASPAC 013 trials suggested that postoperative adjuvant treatment offered a good chance for prolonged survival in patients undergoing curative resection of PC. However, a certain number (30%–40%) of patients cannot receive adjuvant therapy due to postoperative morbidity or a poor general condition.4Neoadjuvant treatment (NAT) was initially initiated for borderline resectable PC (BR‐PC).5 Most reports of treatment outcomes were from retrospective studies, and there were no reports with a high level of evidence. In 2018, a multicenter randomized controlled trial (RCT) was reported from Korea that examined the efficacy of NAT against upfront surgery in BR‐PC.6 In the intention‐to‐treat analysis, the 2‐year survival rate was significantly better in the NAT group than in the upfront surgery group (40.7% vs. 26.1%). Thereafter, although the evidence is limited, the National Comprehensive Cancer Network (NCCN) and Japan Pancreas Society Guidelines recommend NAT for BR‐PC.7,8After the promising results 
TI - Randomized phase II trial of chemoradiotherapy with S‐1 versus combination chemotherapy with gemcitabine and S‐1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
JF - Journal of Hepato-Biliary-Pancreatic Sciences
DO - 10.1002/jhbp.1353
DA - 2023-11-01
UR - https://www.deepdyve.com/lp/wiley/randomized-phase-ii-trial-of-chemoradiotherapy-with-s-1-versus-Hls3Xrm20f
SP - 1249
EP - 1260
VL - 30
IS - 11
DP - DeepDyve
ER -